Cargando…

A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer

Levels of total human kallikrein 2 (hK2), a protein involved the pathology of prostate cancer (PCa), could be used as a biomarker to aid in the diagnosis of this disease. In this study, we report on a porous silicon antibody immunoassay platform for the detection of serum levels of total hK2. The su...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sang Wook, Hosokawa, Kazuo, Kim, Soyoun, Jeong, Ok Chan, Lilja, Hans, Laurell, Thomas, Maeda, Mizuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481930/
https://www.ncbi.nlm.nih.gov/pubmed/26007739
http://dx.doi.org/10.3390/s150511972
_version_ 1782378348872204288
author Lee, Sang Wook
Hosokawa, Kazuo
Kim, Soyoun
Jeong, Ok Chan
Lilja, Hans
Laurell, Thomas
Maeda, Mizuo
author_facet Lee, Sang Wook
Hosokawa, Kazuo
Kim, Soyoun
Jeong, Ok Chan
Lilja, Hans
Laurell, Thomas
Maeda, Mizuo
author_sort Lee, Sang Wook
collection PubMed
description Levels of total human kallikrein 2 (hK2), a protein involved the pathology of prostate cancer (PCa), could be used as a biomarker to aid in the diagnosis of this disease. In this study, we report on a porous silicon antibody immunoassay platform for the detection of serum levels of total hK2. The surface of porous silicon has a 3-dimensional macro- and nanoporous structure, which offers a large binding capacity for capturing probe molecules. The tailored pore size of the porous silicon also allows efficient immobilization of antibodies by surface adsorption, and does not require chemical immobilization. Monoclonal hK2 capture antibody (6B7) was dispensed onto P-Si chip using a piezoelectric dispenser. In total 13 × 13 arrays (169 spots) were spotted on the chip with its single spot volume of 300 pL. For an optimization of capture antibody condition, we firstly performed an immunoassay of the P-Si microarray under a titration series of hK2 in pure buffer (PBS) at three different antibody densities (75, 100 and 145 µg/mL). The best performance of the microarray platform was seen at 100 µg/mL of the capture antibody concentration (LOD was 100 fg/mL). The platform then was subsequently evaluated for a titration series of serum-spiked hK2 samples. The developed platform utilizes only 15 µL of serum per test and the total assay time is about 3 h, including immobilization of the capture antibody. The detection limit of the hK2 assay was 100 fg/mL in PBS buffer and 1 pg/mL in serum with a dynamic range of 10(6) (10(−4) to 10(2) ng/mL).
format Online
Article
Text
id pubmed-4481930
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-44819302015-06-29 A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer Lee, Sang Wook Hosokawa, Kazuo Kim, Soyoun Jeong, Ok Chan Lilja, Hans Laurell, Thomas Maeda, Mizuo Sensors (Basel) Article Levels of total human kallikrein 2 (hK2), a protein involved the pathology of prostate cancer (PCa), could be used as a biomarker to aid in the diagnosis of this disease. In this study, we report on a porous silicon antibody immunoassay platform for the detection of serum levels of total hK2. The surface of porous silicon has a 3-dimensional macro- and nanoporous structure, which offers a large binding capacity for capturing probe molecules. The tailored pore size of the porous silicon also allows efficient immobilization of antibodies by surface adsorption, and does not require chemical immobilization. Monoclonal hK2 capture antibody (6B7) was dispensed onto P-Si chip using a piezoelectric dispenser. In total 13 × 13 arrays (169 spots) were spotted on the chip with its single spot volume of 300 pL. For an optimization of capture antibody condition, we firstly performed an immunoassay of the P-Si microarray under a titration series of hK2 in pure buffer (PBS) at three different antibody densities (75, 100 and 145 µg/mL). The best performance of the microarray platform was seen at 100 µg/mL of the capture antibody concentration (LOD was 100 fg/mL). The platform then was subsequently evaluated for a titration series of serum-spiked hK2 samples. The developed platform utilizes only 15 µL of serum per test and the total assay time is about 3 h, including immobilization of the capture antibody. The detection limit of the hK2 assay was 100 fg/mL in PBS buffer and 1 pg/mL in serum with a dynamic range of 10(6) (10(−4) to 10(2) ng/mL). MDPI 2015-05-22 /pmc/articles/PMC4481930/ /pubmed/26007739 http://dx.doi.org/10.3390/s150511972 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Sang Wook
Hosokawa, Kazuo
Kim, Soyoun
Jeong, Ok Chan
Lilja, Hans
Laurell, Thomas
Maeda, Mizuo
A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer
title A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer
title_full A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer
title_fullStr A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer
title_full_unstemmed A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer
title_short A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer
title_sort highly sensitive porous silicon (p-si)-based human kallikrein 2 (hk2) immunoassay platform toward accurate diagnosis of prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481930/
https://www.ncbi.nlm.nih.gov/pubmed/26007739
http://dx.doi.org/10.3390/s150511972
work_keys_str_mv AT leesangwook ahighlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT hosokawakazuo ahighlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT kimsoyoun ahighlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT jeongokchan ahighlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT liljahans ahighlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT laurellthomas ahighlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT maedamizuo ahighlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT leesangwook highlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT hosokawakazuo highlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT kimsoyoun highlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT jeongokchan highlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT liljahans highlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT laurellthomas highlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer
AT maedamizuo highlysensitiveporoussiliconpsibasedhumankallikrein2hk2immunoassayplatformtowardaccuratediagnosisofprostatecancer